-
11.发明公开
公开(公告)号：EP3489680A3
公开(公告)日：2019-06-12
申请号：EP18201992.7
申请日：2011-07-28
IPC分类号： G01N33/48
摘要： The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio ( RASGRP1:APTX ), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.
-
12.发明授权
公开(公告)号：EP2598874B1
公开(公告)日：2018-10-24
申请号：EP11813168.9
申请日：2011-07-28
IPC分类号： G01N33/48
CPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16
摘要： The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1 :APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (Rl 15777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.
-
13.发明授权METHODS AND COMPOSITION TO GENERATE UNIQUE SEQUENCE DNA PROBES, IABELING OF DNA PROBES AND THE USE OF THESE PROBES 有权方法和组合物作者：DNA PROBES单一序列的DNA探针标记及探针的使用生产
公开(公告)号：EP1941050B1
公开(公告)日：2017-04-26
申请号：EP06844178.1
申请日：2006-09-20
发明人： CONNELLY, Mark, Carle , FOULK, Brad , KAGAN, Michael, T. , SWENNENHUIS, Joost, F. , TERSTAPPEN, Leon, W.M.M. , TIBBE, Arjan, G.J. , VERRANT, John, A.
CPC分类号： C12Q1/6886 , C12Q1/34 , C12Q1/6811 , C12Q1/6876 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2533/101 , C12Q2531/113 , C12Q2521/301 , C12Q2563/131 , C12Q2563/103
摘要： A method for detecting the presence of a target sequence comprising: a. adding a probe, said probe having been produced by a method comprising: i. obtaining double strand polynucleotides known to contain complementary target sequences and repetitive sequences; ii. fragmenting said double strand polynucleotides into fragments; iii. denaturing said fragments into single strands; iv. hybridizing said repetitive sequences to form a mixture of double strands and single strands; v. cleaving said double strands; and vi. amplifying said single strands wherein said single strands are complementary to said target sequences; and b. detecting said probe wherein said detection is selected from a group consisting of ISH, FISH, CGH, spectral karyotyping, chromosome painting, Northern blots, Southern blots, microarray analysis, and combinations thereof.
摘要翻译： 本发明涉及基因集会的DNA序列，基因或染色体识别领域。 被提供的方法和组合物以获得独特序列的DNA探针。 组合物包含任何双链DNA含有来自哪个重复序列被消除gemäß对本发明描述的方法的独特序列的。 因此，本发明涉及细胞免疫磁性选择和为了つ荧光标记后thathave被鉴定weiterer询问感兴趣的细胞的保存。 进一步，本发明涉及细胞免疫磁性选择和荧光标记后thathave被鉴定的遗传分析。
-
公开(公告)号：EP2729802B1
公开(公告)日：2015-05-06
申请号：EP12748286.7
申请日：2012-07-06
CPC分类号： C12Q1/04 , G01N15/1475 , G01N33/5026 , G01N33/5064 , G01N2800/32 , G01N2800/52
-
公开(公告)号：EP2739138A4
公开(公告)日：2015-03-25
申请号：EP12822609
申请日：2012-08-03
发明人： LI ZHIYU , RUSSELL THOMAS , GAO JUN
CPC分类号： C07K1/1077 , B01J20/28009 , B01J20/286 , B01J20/3204 , B01J20/3217 , B01J20/3229 , B01J20/3274 , B01J20/3282 , B01J39/26 , B01J41/20 , C07K1/22 , C07K17/14 , G01N33/532
摘要： Functionalized magnetic particles are emerging as a reliable and convenient technique in the purification of biomacromolecules (proteins and nucleic acids). We disclose a novel coupling procedure that can be used to create stable ferromagnetic nickel particles coated with Protein A for the affinity purification of antibody. The protein purification procedure is gentle, scalable, automatable, efficient and economical. By modifying the functional groups of amino acids in the protein coating, nickel particles can be used not only for affinity purification but for other sample preparation and chromatographic applications as well including nucleic acid isolations. The method can be easily modified for small and medium scale antibody purification in lab and pre-clinical research.
-
公开(公告)号：EP1721159B1
公开(公告)日：2014-12-10
申请号：EP05732080.6
申请日：2005-02-18
发明人： WANG, Yixin
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/154 , C12Q2600/158
-
公开(公告)号：EP2518166B1
公开(公告)日：2014-12-03
申请号：EP12166440.3
申请日：2006-05-18
发明人： Jiang, Yuqiu , Backus, John W. , Mazumder, Abhijit , Chowdary, Dondapati , Yang, Fei , Wang, Yixin , Jatkoe, Timothy
CPC分类号： G01N33/57407 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/154
-
18.发明授权Labeled cells for use as an internal functional control in rare cell detection assays 有权标记的使用的细胞在功能测定的内部对照检测稀有细胞的
公开(公告)号：EP2280283B1
公开(公告)日：2014-10-15
申请号：EP10179790.0
申请日：2002-03-07
IPC分类号： G01N33/574
CPC分类号： B82Y25/00 , B03C1/01 , G01N15/14 , G01N33/574 , G01N33/57484 , G01N33/57492 , H01F1/0054
-
19.发明授权METHODS AND MATERIALS FOR IDENTIFYING THE ORIGIN OF A CARCINOMA OF UNKNOWN PRIMARY ORIGIN 有权方法和材料鉴定癌症原发灶不明起源ORIGIN
公开(公告)号：EP1934615B1
公开(公告)日：2014-06-04
申请号：EP06814892.3
申请日：2006-09-19
IPC分类号： G01N33/574 , G01N33/48 , C12Q1/68
CPC分类号： G01N33/57484 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/5091 , G16H10/40 , Y02A90/26
摘要： The present invention provides a method of identifying origin of a metastasis of unknown origin by obtaining a sample containing metastatic cells; measuring Biomarkers associated with at least two different carcinomas; combining the data from the Biomarkers into an algorithm where the algorithm normalizes the Biomarkers against a reference; and imposes a cut-off which optimizes sensitivity and specificity of each Biomarker, weights the prevalence of the carcinomas and selects a tissue of origin determining origin based on highest probability determined by the algorithm or determining that the carcinoma is not derived from a particular set of carcinomas; and optionally measuring Biomarkers specific for one or more additional different carcinoma, and repeating the steps for additional Biomarkers.
-
20.发明公开STEROID RECEPTOR ASSAYS FOR DETECTING TUMOR CELLS 审中-公开STEROIDREZEPTORTESTSFÜRDEN NACHWEIS VON TUMORZELLEN
公开(公告)号：EP2694971A1
公开(公告)日：2014-02-12
申请号：EP12716825.0
申请日：2012-03-30
发明人： CHIANESE, David, A.
IPC分类号： G01N33/574 , G01N33/74 , G01N33/543
摘要： Methods for the detection, enumeration and analysis of circulating tumor cells expressing steroid receptors, particularly estrogen receptors are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.
摘要翻译： 公开了用于检测，计数和分析表达类固醇受体，特别是雌激素受体的循环肿瘤细胞的方法。 这些方法可用于癌症筛查和分期，治疗方案的开发以及用于监测治疗反应，癌症复发等的方法。 还提供了促进这种循环肿瘤细胞的检测，计数和分析的测试试剂盒。
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.036 秒)
